Hematologic Malignancies

Cardio-Oncology

Questions discussed in this category

In a patient with cardiac light chain amyloid who has significant heart failure symptoms, including inotrope dependence at presentation, how much clinical benefit does treatment provide?

How long would you treat before considering palliative care alone?

1 Answer available

For CLL patients with high-risk cytogenetics on ibrutinib who develop a cardiac event such as an MI, would you continue ibrutinib?

Would you continue ibrutinib even if they are placed on anti-platelet therapy such as clopidogrel or ticagrelor? When do you switch to an altern...

5 Answers available

How do you manage severe hypertriglyceridemia in the adolescent & young adult population receiving chemotherapy for ALL, in the absence of complications related to hypertriglyceridemia?

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2015-12-17

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Blood, 2022 Jul 14

Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.

Leukemia, 2021 Apr 27

Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.

J Am Coll Cardiol, 2019 Oct 01

Cardiovascular Toxicities Associated With Ibrutinib.

American journal of hematology, 2023 Dec 15

Reduced early mortality with Daratumumab-based frontline therapy in AL amyloidosis: A retrospective cohort study.

Blood, 2023 Oct 05

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.

Related Topics in Hematologic Malignancies